Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The serotonin transporter gene promoter polymorphism (5-HTTLPR) has been repeatedly associated with antidepressant response in mood disorder patients, but findings are not consistent across studies. A meta-analysis was performed on 15 studies including data of 1435 subjects. We tested three phenotypes: remission rate, response rate and response rate within 4 weeks using the cochrane review manager. We observed a significant association of the s/s variant of 5-HTTLPR with remission rate (P<0.0001) and both s/s and s/l variants with response rate (P=0.0002). Response rate within 4 weeks was associated in both models (P=0.003-P<0.00001). This effect is quite robust to ethnic differences although a significant heterogeneity is present in Asian samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“L-alleles result in greater mRNA transcription and more active 5-HTT function (Parsey et al., 2006) and have been associated with a better treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants although discrepant findings exist (Serretti et al., 2007).”
From Affective Cognition and its Disruption in Mood Disorders (2011) · cites this paper as Serretti et al., 2007
Citations
Cites
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Hu, X.-Z., Lipsky, R. H., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B. D., Xu, K., Arnold, P. D., Richter, M. A., Kennedy, J. L., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,123
(1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Meta-analysis of genetic association studies
Munafò, M. R., & Flint, J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.06.014 · Cited by 642
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000698 · Cited by 633
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Cited by
Items 101–200 of 535
A pharmacological analysis of mice with a targeted disruption of the serotonin transporter
Fox, M. A., Andrews, A. M., Wendland, J. R., Lesch, K., Holmes, A., & Murphy, D. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0910-0 · Cited by 79
“Future animal research with temporally and spatially regulated conditional disruption of SERT will help to untangle the disparity between findings on the effects of genetic or pharmacologic blockade of SERT in early development compared to pharmacologic blockade of SERT by SRIs later in life.”
ResultInfluentialAlbert, P. R., François, B. L., & Vahid-Ansari, F. (2019) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180209 · Cited by 75
Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression
Baffa, A., Hohoff, C., Baune, B. T., Müller-Tidow, C., Tidow, N., Freitag, C., Zwanzger, P., Deckert, J., Arolt, V., & Domschke, K. (2010) · Neuropsychobiology · doi:10.1159/000317285 · Cited by 71
Huang, E., Zai, C. C. H., Lisoway, A. J., Maciukiewicz, M., Felsky, D., Tiwari, A. K., Bishop, J. R., Ikeda, M., Molero, P., Ortuño, F., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv132 · Cited by 77
“Fixed effects models were used for each analysis, consistent with approaches commonly used in pharmacogenetic meta-analyses (Serretti et al., 2007; Zhang et al., 2010).”
MethodMolecular Genetics of Monoamine Transporters: Relevance to Brain Disorders
Haddley, K., Vasiliou, A. S., Ali, F. R., Paredes, U. M., Bubb, V. J., & Quinn, J. P. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9521-8 · Cited by 74
Serotonin Pathway Polymorphisms and the Treatment of Major Depressive Disorder and Anxiety Disorders
Helton, S. G., & Lohoff, F. W. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.15 · Cited by 68
Guidotti, G., Calabrese, F., Auletta, F., Olivier, J., Racagni, G., Homberg, J. R., & Riva, M. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.252 · Cited by 82
“All rights reserved 0893-133X/12 www.neuropsychopharmacology.org (Caspi et al, 2003; Huezo-Diaz et al, 2009; Serretti et al, 2007; Uher and McGuffin, 2008).”
The relationship between fibromyalgia and major depressive disorder: a comprehensive review
Pae, C., Luyten, P., Marks, D. M., Han, C., Park, S., Patkar, A. A., Masand, P. S., & Houdenhove, B. V. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802288338 · Cited by 80
Maron, E., Tammiste, A., Kallassalu, K., Eller, T., Vasar, V., Nutt, D., & Metspalu, A. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.010 · Cited by 70
“Recently, Serretti et al. (2007) performed a meta-analysis of 5-HTTLPR effect on the antidepressant treatment based on 15 available studies including data of 1435 subjects.”
Binder, E. B., Jeffrey Newport, D., Zach, E. B., Smith, A. K., Deveau, T. C., Altshuler, L. L., Cohen, L. S., Stowe, Z. N., & Cubells, J. F. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.12.001 · Cited by 69
“In contrast, the current data, in agreement with the majority but not all previously reported pharmacogenetic and gene × environment associations (Caspi et al 2003; Serretti et al 2007), suggest that the low function S-allele is the risk allele.”
BackgroundResultInfluentialThe role of genetics and genomics in clinical psychiatry
Hoehe, M. R., & Morris-Rosendahl, D. J. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.3/mhoehe · Cited by 66
Economic evaluation in psychiatric pharmacogenomics: a systematic review
Karamperis, K., Koromina, M., Papantoniou, P., Σκώκου, Μ., Kanellakis, F., Mitropoulos, K. A., Vozikis, A., Müller, D. J., Patrinos, G. P., & Mitropoulou, C. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00249-1 · Cited by 75
The role of pharmacogenetics in the treatment of depression and anxiety disorders
Schosser, A., & Kasper, S. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283306a2f · Cited by 69
“In a recent meta-analysis of 5-HTTLPR association with SSRI efficacy in depression, Serretti et al. (2007) showed that different allele frequencies between Caucasians and Asians (the s allele being present in 42% of Caucasians, but in 79% of Asians) were a strong cause of heterogeneity.”
BackgroundPharmacogenetics of antidepressant response
Keers, R., & Aitchison, K. J. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.186 · Cited by 66
Mackay, G. M., Forrest, C. M., Christofides, J., Bridel, M. A., Mitchell, S., Cowlard, R., Stone, T. W., & Darlington, L. G. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.05077.x · Cited by 66
“Some of the receptor changes may be secondary to chronic changes in 5-HT concentrations,(2) but analyses of nucleotide polymorphisms also suggest a strong link between some aspect of 5-HT metabolism, especially of the serotonin transporter, and the extent of depression or its response to drug treatment.(3,4) Despite t…”
BackgroundIgnácio, Z. M., Réus, G. Z., Abelaira, H. M., & Quevedo, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.036 · Cited by 65
Clinical Implications of Genetic Variation in the Serotonin Transporter Promoter Region: A Review
Luddington, N. S., Mandadapu, A., Husk, M., & El-Mallakh, R. S. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08r00656 · Cited by 46
Udina, M., Moreno-España, J., Navinés, R., Giménez, M. D., Langohr, K., Gratacòs, M., Capuron, L., de la Torre, R., Sola, R. L., & Martín‐Santos, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.007 · Cited by 69
“Subjects with a ‘‘higher transcription genotype’’ (LL homozygote) may present higher serotonin reuptake and therefore be less vulnerable to suffering depression (Caspi et al., 2003), and may also have better response to antidepressants like SSRIs (Serretti et al., 2007).”
Pharmacogenomics with Antidepressants in the STAR*D Study
Lin, E., & Chen, P. S. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.7.935 · Cited by 63
“Since the reports in the STAR*D study design did not include medication-intolerant patients who were less likely to respond to treatment, the association with treatment response in some small studies [31–38] and the recent meta-analysis [30] might actually represent an association with tolerance [28].”
ResultCoventry, W. L., James, M. R., Eaves, L. J., Gordon, S. D., Gillespie, N. A., Ryan, L., Heath, A. C., Montgomery, G. W., Martin, N. G., & Wray, N. R. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31044 · Cited by 61
“2009 Wiley-Liss, Inc. 757 Neuropsychiatric Genetics 5HTTLPR [Li and He, 2007] and an inconsistent association between MD and 5HTTLPR with effects observed by some [Serretti et al., 2007; Lopez-Leon et al., 2008] but not others [Anguelova et al., 2003; Lasky-Su et al., 2005; Levinson, 2005].”
BackgroundPharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review
Wehry, A. M., Ramsey, L., Dulemba, S. E., Mossman, S. A., & Strawn, J. R. (2018) · Current Problems in Pediatric and Adolescent Health Care · doi:10.1016/j.cppeds.2017.12.003 · Cited by 62
“0001).(19) Other variants in this gene may also be associated with expression of the transporter, adverse reactions and response to SSRIs.”
Psychotherapy and Genetic Neuroscience: An Emerging Dialog
Jiménez, J. P., Botto, A., Herrera, L., Leighton, C., Rossi, J. L., Quevedo, Y., Silva, J. R., Martínez, F. I., Assar, R., Salazar, L. A., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00257 · Cited by 67
A critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Silva, H., Iturra, P., Solari, A., Villarroel, J., Jerez, S., Jiménez, M., Galleguillos, F., & Bustamante, M. L. (2010) · Psychiatric Genetics · doi:10.1097/ypg.0b013e328335125d · Cited by 59
“, 2006), and meta-analytical techniques (Serretti et al., 2007) that gather data from many patients, the association of the l variant with a better SSRI response has been confirmed.”
BackgroundMethodGonda, X., Fountoulakis, K. Ν., Ríhmer, Z., Lazáry, J., Lászik, A., Akiskal, K. K., Akiskal, H. S., & Bagdy, G. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.012 · Cited by 61
Bishop, J. R., Ellingrod, V. L., Akroush, M., & Moline, J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1006 · Cited by 62
“Previous investigations of the relationship of 5HTTLPR genotypes with response and side effect outcomes in patients taking SSRIs have largely associated the ll genotype with both better response and fewer side effects in Caucasian study samples (Serretti et al., 2007; Smits et al., 2007).”
Vrshek-Schallhorn, S., Stroud, C. B., Mineka, S., Zinbarg, R. E., Adam, E. K., Redei, E. E., Hammen, C., & Craske, M. G. (2015) · Journal of Abnormal Psychology · doi:10.1037/abn0000098 · Cited by 55
Vahid-Ansari, F., Zhang, M., Zahrai, A., & Albert, P. R. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00404 · Cited by 67
Zanardi, R., Magri, L., Rossini, D., Malaguti, A., Giordani, S., Lorenzi, C., Pirovano, A., Smeraldi, E., & Lucca, A. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.008 · Cited by 59
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms
Reynolds, G. P., McGowan, O. O., & Dalton, C. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12312 · Cited by 65
User considerations in assessing pharmacogenomic tests and their clinical support tools
Mukerjee, G., Huston, A., Kabakchiev, B., Piquette‐Miller, M., van Schaik, R. H., & Dorfman, R. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0065-4 · Cited by 64
Tatham, E. L., Hall, G. B. C., Clark, D., Foster, J. A., & Ramasubbu, R. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0702-9 · Cited by 57
Fabbri, C., Porcelli, S., & Serretti, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900202 · Cited by 64
Self-citationLanctôt, K. L., Rapoport, M. J., Chan, F., Rajaram, R. D., Strauss, J., Sicard, T., McCullagh, S., Feinstein, A., Kiss, A., Kennedy, J. L., et al. (2010) · Brain Injury · doi:10.3109/02699051003789229 · Cited by 54
“mood disorder patients [30].”
BackgroundResultMaier, W., & Zobel, A. W. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-1004-z · Cited by 57
Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial
Lewis, G., Mulligan, J., Wiles, N., Cowen, P., Craddock, N., Ikeda, M., Grozeva, D., Mason, V., Nutt, D., Sharp, D., et al. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.082727 · Cited by 58
Daws, L. C., Koek, W., & Mitchell, N. C. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn3001872 · Cited by 58
The genetics of selective serotonin reuptake inhibitors
Kroeze, Y., Zhou, H., & Homberg, J. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.015 · Cited by 60
“These and other studies have been evaluated in several meta-analyses and reviews of Kato and Serretti (2010), Serretti et al. (2005, 2006, 2007), and Weizman and Weizman (2000).”
Genetics of smoking and depression
Tsuang, M. T., Francis, T., Minor, K. S., Thomas, A., & Stone, W. S. (2012) · Human Genetics · doi:10.1007/s00439-012-1170-6 · Cited by 59
“Some have shown support for the short allele conferring a greater risk of depression (Furlong et al. 1998), and a poorer response to SSRIs compared to those with the longer allele (Serretti et al. 2007a, b).”
BackgroundAndreescu, C., & Reynolds, C. F. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.02.005 · Cited by 52
“Various candidate genes in the serotoninergic system (most notably the serotonin transporter polymorphism) have been associated with treatment response.(90) The serotonin transporter gene (SLC6A4) also influences treatment response variability in LLD, mainly in the initial stages of treatment, through a gene-concentra…”
BackgroundIgnácio, Z. M., Réus, G. Z., Abelaira, H. M., Maciel, A. L., de Moura, A. B., Matos, D., Demo, J. P., da Silva, J. B. I., Gava, F. F., Valvassori, S. S., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.11.044 · Cited by 53
Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
Pharmacology of serotonin and female sexual behavior
Uphouse, L. L. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.008 · Cited by 56
“…their association with female HSDD and/or after treatment with 5-HT system altering drugs (Bishop et al., 2009; Bishop et al., 2006; Burri et al., 2012; Serretti et al., 2007) may begin to offer a profile aboutwhich components of the 5-HT system are especially important in female sexual behavior.”
BackgroundFrom Psychiatric Disorders to Animal Models: A Bidirectional and Dimensional Approach
Donaldson, Z. R., & Hen, R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.02.004 · Cited by 50
Serotonin transporter gene polymorphism and psychiatric disorders: Is there a link?
Margoob, M., & Mushtaq, D. (2011) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.91901 · Cited by 76
“A meta-analysis performed on 15 studies by Serretti et al. (2007) [64] observed a significant association of the S/S variant of 5-HTTLPR with remission rate and of both S/S and S/L variants with response rate.”
Ruhé, H. G., Ooteman, W., Booij, J., Michel, M. C., Moeton, M., Baas, F., & Schene, A. H. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32831a6a3a · Cited by 49
Li, J. J., Berk, M. S., & Lee, S. S. (2013) · Development and Psychopathology · doi:10.1017/s0954579413000321 · Cited by 55
“Future studies should prioritize examining a wider range of polymorphisms in regions that are proximal to the gene of interest, because certain polymorphisms may act as enhancers or silencers (i.e., epistasis) to other nearby polymorphisms (Serretti et al., 2006).”
BackgroundSchiele, M. A., Zwanzger, P., Schwarte, K., Arolt, V, Baune, B. T., & Domschke, K. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa081 · Cited by 50
“Meta-analytic evidence points to impaired antidepressant treatment response in carriers of the less active 5-HTTLPR S allele in European, but not Asian populations (Serretti et al., 2007; Porcelli et al., 2012), though the effect is likely of only small magnitude (odds ratio = 1.”
BackgroundMinelli, A., Bonvicini, C., Scassellati, C., Sartori, R., & Gennarelli, M. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-50 · Cited by 57
“According to recent findings, the S allele is associated with a less favorable response/resistance to pharmacological treatment [5-8] but also with central stress regulation [9-11].”
BackgroundPharmacogenetics of antidepressant response: An update
Drago, A., De Ronchi, D., & Serretti, A. (2008) · Human Genomics · doi:10.1186/1479-7364-3-3-257 · Cited by 51
“Carriers of this allele were found to benefit from a higher density of serotonin transporters on the surface of their neurones, which may be related to a more antidepressant drug-responsive serotonergic system, given that the serotonin transporter is the putative key target of the antidepressant effect.(29) This has b…”
BackgroundSelf-citationMarkus, C. R., & Raedt, R. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.221 · Cited by 52
“This region encodes the 5-HT transporter protein (5-HTT) that controls 5- HT reuptake and function and which is the main target mechanism for antidepressant drugs (Serretti et al, 2007).”
BackgroundDolžan, V., Serretti, A., Mandelli, L., Koprivšek, J., Kastelic, M., & Plesničar, B. K. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.022 · Cited by 50
Self-citationThe Promise and Reality of Pharmacogenetics in Psychiatry
Zandi, P. P., & Judy, J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.001 · Cited by 56
Genome-wide association studies of antidepressant outcome: A brief review
Laje, G., & McMahon, F. J. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.031 · Cited by 47
Ren, F., Ma, Y.-F., Zhu, X.-C., Guo, R.-J., Wang, J.-L., & He, L.-J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.04.058 · Cited by 33
Interaction between SERTPR and stressful life events on response to antidepressant treatment
Mandelli, L., Marino, E., Pirovano, A., Calati, R., Zanardi, R., Colombo, C., & Serretti, A. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.005 · Cited by 50
Self-citationOo, K. Z., Aung, Y. K., Jenkins, M. A., & Win, A. K. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416637920 · Cited by 45
“In another meta-analysis that investigated the association of 5HTTLPR with SSRI efficacy, it was again demonstrated that the L allele of 5HTTLPR polymorphism has association with better response to antidepressant (Serretti et al., 2007).”
BackgroundResultTatham, E. L., Ramasubbu, R., Gaxiola‐Valdez, I., Cortese, F., Clark, D., Goodyear, B. G., Foster, J. A., & Hall, G. B. (2016) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2016.04.014 · Cited by 50
Effects of BDNF Polymorphisms on Antidepressant Action
Tsai, S.-J., Hong, C.-J., & Liou, Y.-J. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.4.236 · Cited by 49
Optogenetic Control of Serotonin and Dopamine Release in Drosophila Larvae
Xiao, N., Champaloux, E. P., & Venton, B. J. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500044b · Cited by 51
Serretti, A., Chiesa, A., Calati, R., Perna, G., Bellodi, L., & De Ronchi, D. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32831db2d7 · Cited by 48
“…and that only a careful analysis of the network of their reciprocal interconnections can give a more complete view of the complexity of the possible interactions (Caspi et al., 2003; Serretti et al., 2007a, 2007b, 2007c), although this has been proven to be quite difficult (Winterer et al., 1998).”
BackgroundMethodResultInfluentialSelf-citationMcGuffin, P., Alsabban, S., & Uher, R. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.085225 · Cited by 47
Kelley, M. E., Dunlop, B. W., Nemeroff, C. B., Lori, A., Carrillo-Roa, T., Binder, E. B., Kutner, M. H., Rivera, V. A., Craighead, W. E., & Mayberg, H. S. (2018) · Depression and Anxiety · doi:10.1002/da.22832 · Cited by 43
The genetics of the serotonin transporter and irritable bowel syndrome
Colucci, R., Blandizzi, C., Bellini, M., Ghisu, N., Tonini, M., & Tacca, M. D. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.05.001 · Cited by 55
Lohoff, F. W., Narasimhan, S., & Rickels, K. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.33 · Cited by 47
Rogers, J., Li, S., Lanfumey, L., Hannan, A. J., & Renoir, T. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.06.009 · Cited by 52
“In addition, a meta-analysis determined that 5-HTTLPR s carriers associated with reduced response rate to this type of antidepressant treatment [20] so this population of patients have a specific need for such novel therapies.”
BackgroundKang, R.-H., Wong, M., Choi, M.-J., Paik, J., & Lee, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.018 · Cited by 50
“However, a meta-analysis of previous researches by Serretti et al. (2007) reported that l-allele carriers nsporter promoter polymorphism and mirtazapine antidepressant response in doi:10.1016/j.pnpbp.2007.05.018 LOCF (last-observation-carried-forward) analysis was performed for missing data in HAMD…”
InfluentialNg, C. H., Sarris, J. J., Singh, A., Bousman, C., Byron, K. A., Peh, L. H., Smith, D. J., Tan, C. H., & Schweitzer, I. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2340 · Cited by 49
“However, a variety of minor effect genes may be involved (Serretti et al., 2007).”
BackgroundMethodInfluentialAnalysis of 34 candidate genes in bupropion and placebo remission
Tiwari, A. K., Zai, C. C. H., Sajeev, G., Arenovich, T., Müller, D. J., & Kennedy, J. L. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000843 · Cited by 45
Serotonin transporter gene polymorphisms and treatment-resistant depression
Bonvicini, C., Minelli, A., Scassellati, C., Bortolomasi, M., Segala, M., Sartori, R., Giacopuzzi, M., & Gennarelli, M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.020 · Cited by 54
“In our study we compared TRD patients versus controls; however the involvement of L allele in MDD patient responders to SSRIs monotherapywas largely supported by numerous studies (see for review Horstmann and Binder, 2009).”
BackgroundInfluentialUmene-Nakano, W., Yoshimura, R., Ueda, N., Suzuki, A., Ikenouchi-Sugita, A., Hori, H., Otani, K., & Nakamura, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106899 · Cited by 46
“Furthermore, a recent meta-analysis of the 5-HTTLPR association with SSRI efficacy (Serretti et al., 2007) confirmed the significant association of the l variant of 5-HTTLPR with a better response to SSRIs; this effect appeared to be independent of ethnicity.”
BackgroundBrain imaging, genetics and emotion
Aleman, A., Swart, M., & van Rijn, S. (2008) · Biological Psychology · doi:10.1016/j.biopsycho.2008.01.009 · Cited by 51
“Interestingly, an effect of 5-HTTLPR variants has been implicated in efficacy of SSRIs in depressed patients (Serretti et al., 2007).”
BackgroundKosek, E., Martinsen, S., Gerdle, B. U. C., Mannerkorpi, K., Löfgren, M., Bilevičiūtė-Ljungar, I., Fransson, P., Schalling, M., Ingvar, M., Ernberg, M. M., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.07.150 · Cited by 50
“Since SSRIs promote the synthesis of neurosteroids with analgesic effects (Kawano et al., 2011; Pinna et al., 2006; Serretti et al., 2007), this mechanism could hypothetically explain why SSRIs can have beneficial effects on FM symptoms (Carville et al.”
BackgroundMethodMushtaq, D., Ali, A., Margoob, M. A., Murtaza, I., & Andrade, C. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.033 · Cited by 44
“In Table 1, we summarize the results of studies of the role of the 5HTTLPR in the antidepressant response to SSRIs.”
BackgroundInfluentialThe Involvement of Genes in Adolescent Depression: A Systematic Review
Xia, L., & Yao, S. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00329 · Cited by 48
“A meta-analysis has demonstrated that the 5-HTTLPR long-allele carriers had higher probability of response than patients with short-allele homozygotes of 5-HTTLPR with heterogeneity effect (Serretti et al., 2007).”
BackgroundBiernacka, J. M., McElroy, S. L., Crow, S. J., Sharp, A., Benitez, J., Veldić, M., Kung, S., Cunningham, J. M., Post, R. M., Mrazek, D. A., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.038 · Cited by 43
“A recent meta-analysis concluded that the LL genotype, in contrast to SL and SS genotypes, is associated with a higher response rate to SSRI treatment in patients with unipolar or bipolar depression (Serretti et al., 2007).”
ResultLolak, S., Suwannarat, P., & Lipsky, R. H. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800977-2.00005-x · Cited by 46
Pharmacogenomics of antidepressant treatment effects
Licinio, J., & Wong, M.-L. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/jlicinio · Cited by 45
“00001).(12) In subsequent systematic reviews Horstmann and Binder identified 27 pharmacogenetic studies of the association of 5-HTTLPR and treatment response,(13) while Porcelli et al identified 58 such studies.”
Bozina, N., Mihaljevic Peles, A., Sagud, M., Bilusic, H., & Jakovljevic, M. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701308397 · Cited by 42
“Our results are also in agreement with data presented by Serretti et al. (2006).”
ResultImaging genetics studies on monoaminergic genes in major depressive disorder
Won, E., & Ham, B. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.014 · Cited by 44
Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy
Thompson, M. D., & Kenna, G. A. (2015) · Alcohol and Alcoholism · doi:10.1093/alcalc/agv090 · Cited by 42
“Depressed patients with and without concurrent diagnosis of late-onset ADmay bemore likely to respond to SSRls if they carry the L allele (Serretti et al., 2007;Muhonen et al., 2011).”
BackgroundOlgiati, P., Bajo, E., Bigelli, M., Ronchi, D. D., & Serretti, A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.013 · Cited by 44
“The effect size of 5- HTTLPR modulation of SSRI response is estimated from a meta-analysis of randomized trials (Serretti et al., 2007).”
InfluentialSelf-citationSerretti, A., Olgiati, P., Bajo, E., Bigelli, M., & De Ronchi, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.572998 · Cited by 42
Self-citation5-HTTLPR modulates antidepressant efficacy in depressed women
Gressier, F., Bouaziz-Amar, É., Verstuyft, C., Hardy, P., Becquemont, L., & Corruble, E. (2009) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32832cef0d · Cited by 41
“Whatever, Serretti et al. (2007) in a meta-analysis 0955-8829 c 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI: 10.1097/YPG.0b013e32832cef0d performed on 15 studies found no heterogeneity among ethnic differences.”
BackgroundInfluentialBukh, J. D., Bock, C., Vinberg, M., Werge, T. M., Gether, U., & Kessing, L. V. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.11.004 · Cited by 41
Pharmacogenetics of Obsessive–Compulsive Disorders
Brandl, E. J., Müller, D. J., & Richter, M. A. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.133 · Cited by 40
Brunoni, A. R., Carracedo, Á., Maroñas, O., Latorre, A., Talib, L. L., Carvalho, A. F., Lotufo, P. A., Benseñor, I. M., Gattaz, W. F., & Cappi, C. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0620 · Cited by 40
Castellini, G., Ricca, V., Lelli, L., Bagnoli, S., Lucenteforte, E., Faravelli, C., Sorbi, S., & Nacmias, B. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32052 · Cited by 39
“The S-allele was supposed to be associated with a number of serotonin-related phenotypes, such as the risk of developing a bipolar disorder [Cho et al., 2005; Lasky-Su et al., 2005], violent suicide [Lin and Tsai, 2004] and poor antidepressant response [Serretti et al., 2007].”
BackgroundInfluentialSbrini, G., Brivio, P., Bosch, K., Homberg, J. R., & Calabrese, F. (2020) · Genes · doi:10.3390/genes11111248 · Cited by 39
“Unfortunately, first-line antidepressant treatment is only partially effective in treating mood disorders [29], possibly because the target of first-line antidepressant treatment, the 5-HTT, is reduced in those vulnerable to depression [30,31].”
BackgroundPharmacogenetic considerations in the treatment of psychiatric disorders
Lohoff, F., & Ferraro, T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903508762 · Cited by 43
“Whereas a clear correlation between drug plasma levels and therapeutic antidepressant efficacy has been described for tricyclic antidepressants (TCAs) [21], this is less apparent for SSRIs and SNRIs [22].”
BackgroundInfluentialPerspectives on genetic animal models of serotonin toxicity
Kalueff, A. V., LaPorte, J. L., & Murphy, D. L. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.08.015 · Cited by 39
“…predictor of the risks of SS) is related to genetic polymorphisms in human SERT (Smeraldi et al., 1998; Arias et al., 2005; Hu et al., 2007; Serretti et al., 2006, 2007), indicating the likely importance of SERT in SS (also see similar data on genetic polymorphisms in human 5HTR2A; D.L.…”
Pharmacogenetics and Psychiatric Care: A Review and Commentary
Butler, M. G. (2018) · JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY · doi:10.29245/2578-2959/2018/2.1120 · Cited by 37
Behavioural Genetics of the Serotonin Transporter
Haddley, K., Bubb, V. J., Breen, G. D., Esquivel, U. P., & Quinn, J. P. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_186 · Cited by 40
Strohmaier, J., Wüst, S., Uher, R., Henigsberg, N., Mors, O. N., Hauser, J., Souery, D., Zobel, A. W., Dernovšek, M. Z., Streit, F., et al. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.559270 · Cited by 40
“An association has been reported between 5-HTTLPR genotype and response to antidepressant treatment, in which carriers of the long allele show a better response than short allele homozygotes (Serretti et al. 2007; HuezoDiaz et al. 2009).”
BackgroundAntidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction
Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107998 · Cited by 36
Willner, P., Scheel-Krüger, J., & Belzung, C. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000066 · Cited by 36
“] The parallel finding is that individuals homozygous for the short allele of the 5HTTLPR gene are less responsive to antidepressant treatment than individuals homozygous for the long allele, with heterozygotes showing an intermediate response (Serretti et al., 2007; Zobel and Maier, 2010; Licinio and Wong, 2011).”
BackgroundThe genetic blueprint of major depressive disorder: Contributions of imaging genetics studies
Scharinger, C., Rabl, U., Pezawas, L., & Kasper, S. F. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.596220 · Cited by 38
“…its role in predicting behavioural phenotypes such as neuroticism (Munafo et al. 2009), MDD (Risch et al. 2009; Clarke et al. 2010), or antidepressant response (Serretti et al. 2007; Taylor et al. 2010) is at least one order of magnitude lower, likely ranging around 1 – 3% (Serretti et al. 2007).”
BackgroundGene × environment interactions in the prediction of response to antidepressant treatment
Klengel, T., & Binder, E. B. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001459 · Cited by 34
“In fact, previous studies have reported a worse response to SSRI treatment (Serretti et al., 2007) as well as an increased responsiveness to negative life events (Caspi et al.”
InfluentialRaab, K., Kirsch, P., & Mier, D. U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.08.031 · Cited by 37
“Furthermore, 5-HTT polymorphism effects on the efficacy of antidepressants have been reported (Karlović and Karlović, 2013; Porcelli et al., 2012; Serretti et al., 2007; Smits et al., 2004).”
BackgroundGeugies, H., Opmeer, E. M., Marsman, J. B. C., Figueroa, C. A., van Tol, M. J., Schmaal, L., van der Wee, N. J. A., Aleman, A., Penninx, B. W. J. H., Veltman, D. J., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102064 · Cited by 33
“European) (Serretti et al., 2007) or cultural differences (Li et al.”
Metadata
- Authors
- Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T.
- Affiliations
- University of Bologna (IT)
- Kansai Medical University (JP)
- Corresponding author
- Serretti, A
- Venue
- Molecular Psychiatry
- Published
- 2006-12-05
- Volume
- 12
- Issue
- 3
- Pages
- 247-257
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1982886582
- Cited by
- 529
- References
- 51
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 12 · 2021: 44 · 2020: 10 · 2019: 18 · 2018: 22 · 2017: 23 · 2016: 28 · 2015: 29 · 2014: 23 · 2013: 38 · 2012: 39
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- 5-HTTLPR, serotonin transporter gene, promoter polymorphism, selective serotonin reuptake inhibitors, antidepressant response, depression, remission rate, genetic association, ethnic differences, Asian populations
- MeSH terms
- Adult, Aged, Depressive Disorder, Female, Humans, Male, Middle Aged, Polymorphism, Genetic, Promoter Regions, Genetic, MEDLINE, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.